Natera (NASDAQ:NTRA) had its price objective increased by stock analysts at Robert W. Baird from $17.00 to $20.00 in a research note issued on Thursday. The firm presently has an “outperform” rating on the medical research company’s stock. Robert W. Baird’s price objective indicates a potential upside of 6.27% from the company’s previous close.
A number of other analysts have also recently weighed in on NTRA. BidaskClub cut shares of Natera from a “sell” rating to a “strong sell” rating in a report on Wednesday, February 28th. Craig Hallum assumed coverage on shares of Natera in a report on Monday, April 9th. They set a “buy” rating and a $16.00 target price for the company. ValuEngine raised shares of Natera from a “sell” rating to a “hold” rating in a research note on Wednesday, April 11th. Morgan Stanley raised their price objective on shares of Natera from $15.00 to $16.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 9th. Finally, Zacks Investment Research raised shares of Natera from a “sell” rating to a “hold” rating in a research note on Friday, June 8th. One analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. The company has an average rating of “Buy” and an average target price of $18.33.
Shares of NASDAQ:NTRA opened at $18.82 on Thursday. The company has a market cap of $1.03 billion, a P/E ratio of -7.84 and a beta of 2.07. Natera has a 1-year low of $7.78 and a 1-year high of $20.00. The company has a quick ratio of 1.68, a current ratio of 1.80 and a debt-to-equity ratio of -18.90.
Natera (NASDAQ:NTRA) last issued its earnings results on Tuesday, May 8th. The medical research company reported ($0.61) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.60) by ($0.01). The business had revenue of $62.34 million for the quarter, compared to the consensus estimate of $54.86 million. Natera had a negative return on equity of 752.93% and a negative net margin of 58.84%. The company’s quarterly revenue was up 26.2% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.70) earnings per share. sell-side analysts anticipate that Natera will post -2.05 EPS for the current year.
In related news, COO Steven Leonard Chapman sold 86,919 shares of the firm’s stock in a transaction that occurred on Monday, June 25th. The shares were sold at an average price of $18.00, for a total value of $1,564,542.00. Following the completion of the transaction, the chief operating officer now owns 3,588 shares of the company’s stock, valued at approximately $64,584. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Claremont Creek Partners Fund sold 25,027 shares of the stock in a transaction that occurred on Wednesday, May 16th. The stock was sold at an average price of $11.59, for a total transaction of $290,062.93. The disclosure for this sale can be found here. Insiders sold a total of 151,494 shares of company stock valued at $2,310,364 in the last ninety days. Company insiders own 13.18% of the company’s stock.
A number of hedge funds have recently added to or reduced their stakes in NTRA. Schwab Charles Investment Management Inc. lifted its position in Natera by 13.3% in the 4th quarter. Schwab Charles Investment Management Inc. now owns 154,467 shares of the medical research company’s stock worth $1,389,000 after buying an additional 18,187 shares in the last quarter. Wells Fargo & Company MN lifted its position in Natera by 69.3% in the 4th quarter. Wells Fargo & Company MN now owns 51,644 shares of the medical research company’s stock worth $464,000 after buying an additional 21,140 shares in the last quarter. Citadel Advisors LLC lifted its position in Natera by 11.0% in the 4th quarter. Citadel Advisors LLC now owns 112,830 shares of the medical research company’s stock worth $1,014,000 after buying an additional 11,199 shares in the last quarter. Geode Capital Management LLC lifted its position in Natera by 4.0% in the 4th quarter. Geode Capital Management LLC now owns 352,850 shares of the medical research company’s stock worth $3,172,000 after buying an additional 13,708 shares in the last quarter. Finally, Jefferies Group LLC purchased a new stake in Natera in the 4th quarter worth approximately $130,000. Institutional investors own 69.44% of the company’s stock.
Natera Company Profile
Natera, Inc, a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus typically with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.
Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.